President Cyril Ramaphosa and South African government officials launched the national rollout of Lenacapavir, a twice-yearly injectable drug for HIV prevention, on Friday [1].
The rollout arrives as the country struggles with a significant treatment gap, where millions of patients have fallen out of care. By introducing a long-acting preventative measure, the government aims to strengthen its long-term response strategy and lower the rate of new infections.
President Ramaphosa said the new medical tool "offers hope in the fight against HIV/AIDS" [2]. Other government officials said the launch was "a turning point" for the national health strategy [3].
The initiative targets an initial group of 400,000 people [4]. This deployment is critical given the scale of the current crisis regarding antiretroviral (ARV) treatment. Data indicates that 1.1 million people have defaulted on their ARV treatment [5].
Regional challenges further highlight the urgency of the rollout. In Gauteng alone, 326,000 people need to be initiated or re-initiated on treatment [6]. The transition to a twice-yearly injection schedule is intended to reduce the burden of daily medication and improve adherence rates across the population.
Lenacapavir differs from traditional prevention methods by requiring only two doses per year [7]. This frequency is designed to remove the barriers associated with daily pill regimens, which often lead to the treatment defaults mentioned by health officials.
“"This is a turning point"”
The shift toward long-acting injectables like Lenacapavir represents a strategic pivot in South Africa's public health approach. By reducing the frequency of dosing from daily to twice yearly, the government is attempting to solve the systemic issue of patient attrition and treatment default. If successful, this could significantly lower the community viral load and prevent the collapse of care for the hundreds of thousands of patients currently off their medication.
